HomeCompareSNPHF vs CHD

SNPHF vs CHD: Dividend Comparison 2026

SNPHF yields 2.31% · CHD yields 1.27%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 SNPHF wins by $21.8K in total portfolio value
10 years
SNPHF
SNPHF
● Live price
2.31%
Share price
$10.99
Annual div
$0.25
5Y div CAGR
33.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$48.2K
Annual income
$8,450.71
Full SNPHF calculator →
CHD
CHD
● Live price
1.27%
Share price
$93.91
Annual div
$1.19
5Y div CAGR
23.1%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$26.4K
Annual income
$1,292.51
Full CHD calculator →

Portfolio growth — SNPHF vs CHD

📍 SNPHF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSNPHFCHD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SNPHF + CHD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SNPHF pays
CHD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SNPHF
Annual income on $10K today (after 15% tax)
$196.32/yr
After 10yr DRIP, annual income (after tax)
$7,183.10/yr
CHD
Annual income on $10K today (after 15% tax)
$107.94/yr
After 10yr DRIP, annual income (after tax)
$1,098.63/yr
At 15% tax rate, SNPHF beats the other by $6,084.47/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SNPHF + CHD for your $10,000?

SNPHF: 50%CHD: 50%
100% CHD50/50100% SNPHF
Portfolio after 10yr
$37.3K
Annual income
$4,871.60/yr
Blended yield
13.07%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on CHD right now

SNPHF
No analyst data
CHD
Analyst Ratings
18
Buy
15
Hold
1
Sell
Consensus: Buy
Price Target
$98.40
+4.8% upside vs current
Range: $82.00 — $110.00
Altman Z
4.9
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SNPHF buys
0
CHD buys
0
No recent congressional trades found for SNPHF or CHD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSNPHFCHD
Forward yield2.31%1.27%
Annual dividend / share$0.25$1.19
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR33.6%23.1%
Portfolio after 10y$48.2K$26.4K
Annual income after 10y$8,450.71$1,292.51
Total dividends collected$24.8K$5.5K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples

Year-by-year: SNPHF vs CHD ($10,000, DRIP)

YearSNPHF PortfolioSNPHF Income/yrCHD PortfolioCHD Income/yrGap
1← crossover$11,009$308.57$10,856$156.32+$153.00SNPHF
2$12,203$424.14$11,811$195.24+$392.00SNPHF
3$13,645$587.05$12,883$244.38+$762.00SNPHF
4$15,419$819.56$14,091$306.64+$1.3KSNPHF
5$17,655$1,156.39$15,463$385.88+$2.2KSNPHF
6$20,544$1,653.23$17,033$487.17+$3.5KSNPHF
7$24,384$2,402.01$18,843$617.36+$5.5KSNPHF
8$29,651$3,559.74$20,947$785.72+$8.7KSNPHF
9$37,131$5,404.68$23,419$1,004.91+$13.7KSNPHF
10$48,181$8,450.71$26,350$1,292.51+$21.8KSNPHF

SNPHF vs CHD: Complete Analysis 2026

SNPHFStock

Santen Pharmaceutical Co., Ltd. researches and develops, manufactures, and markets pharmaceuticals and medical devices in Japan and internationally. It offers various pharmaceutical products to treat glaucoma and ocular hypertension, such as DE-111, which is in Phase III clinical trial; DE-117 in Japan; DE-126 that is in Phase IIb clinical trial; DE-128 in Europe, as well as is in Phase II/III clinical trial in the United States; and DE-130A that is in Phase III clinical trial. In addition, the company provides DE-114A to treat allergic conjunctivitis; DE-076C for the treatment of vernal keratoconjunctivitis; and DE-109, which is in Phase III clinical trial to treat uveitis. Further, it offers DE-127 to treat myopia, which is in Phase II/III clinical trial in Japan, as well as is in Phase III in Asia; DE-089C, which has completed Phase III clinical trials for the treatment of dry eye; and STN1013400, which is in Phase I clinical trials for the treatment of myopia. Additionally, the company offers over-the-counter pharmaceutical products. The company was formerly known as Santendo Pharmaceutical Co., Ltd. and changed its name to Santen Pharmaceutical Co., Ltd. in 1958. Santen Pharmaceutical Co., Ltd. was founded in 1890 and is headquartered in Osaka, Japan.

Full SNPHF Calculator →

CHDConsumer Staples

Church & Dwight Co., Inc. develops, manufactures, and markets household, personal care, and specialty products. It operates through three segments: Consumer Domestic, Consumer International, and Specialty Products Division. The company offers cat litters, carpet deodorizers, laundry detergents, and baking soda, as well as other baking soda based products under the ARM & HAMMER brand; condoms, lubricants, and vibrators under the TROJAN brand; stain removers, cleaning solutions, laundry detergents, and bleach alternatives under the OXICLEAN brand; battery-operated and manual toothbrushes under the SPINBRUSH brand; home pregnancy and ovulation test kits under the FIRST RESPONSE brand; depilatories under the NAIR brand; oral analgesics under the ORAJEL brand; laundry detergents under the XTRA brand; gummy dietary supplements under the L'IL CRITTERS and VITAFUSION brands; dry shampoos under the BATISTE brand; water flossers and replacement showerheads under the WATERPIK brand; FLAWLESS products; cold shortening and relief products under the ZICAM brand; and oral care products under the THERABREATH brand. Its specialty products include animal productivity products, such as MEGALAC rumen bypass fat, a supplement that enables cows to maintain energy levels during the period of high milk production; BIO-CHLOR and FERMENTEN, which are used to reduce health issues associated with calving, as well as provides needed protein; and CELMANAX refined functional carbohydrate, a yeast-based prebiotic. The company offers sodium bicarbonate; and cleaning and deodorizing products. It sells its consumer products through supermarkets, mass merchandisers, wholesale clubs, drugstores, convenience stores, home stores, dollar and other discount stores, pet and other specialty stores, and websites and other e-commerce channels; and specialty products to industrial customers and livestock producers through distributors. The company was founded in 1846 and is headquartered in Ewing, New Jersey.

Full CHD Calculator →
📬

Get this SNPHF vs CHD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SNPHF vs SCHDSNPHF vs JEPISNPHF vs OSNPHF vs KOSNPHF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.